Table 2.
Body composition and liver-related measurements
| Variables, median (range) | All n = 80 | Men n = 51 | Women n = 29 | P |
|---|---|---|---|---|
| Body composition | ||||
| L3 MI (cm2/m2) | 45.3 (28.7–71.9) | 50.7 (31.9–68.3) | 41.6 (28.7–71.9) | <0.001 |
| Sarcopenia (%) | 31 (38.8) | 18 (35.3) | 13 (44.8) | 0.400 |
| Fat-free body mass (kg) | 47.3 (31.7–75.9) | 54.2 (37.7–67.4) | 39.8 (31.7–75.9) | <0.001 |
| Fat mass (kg) | 29.0 (1.9–86.0) | 28.6 (1.9–45.6) | 29.2 (8.3–86.0) | 0.296 |
| Body fat (%) | 36.5 (2.9–64.2) | 34.8 (2.9–49.7) | 43.5 (17.5–64.2) | 0.001 |
| Obesity (%) | 32 (40.0) | 21 (41.2) | 11 (37.9) | 0.776 |
| Sarcopenic obesity | 18 (22.5) | 15 (29.4) | 3 (10.3) | 0.050 |
| Body surface area (m2) | 1.9 (1.4–2.5) | 2.0 (1.5–2.4) | 1.81 (1.42–2.52) | 0.001 |
| Liver volume | ||||
| Total liver volume (mL) | 1680 (1067–3883) | 1844 (1142–3883) | 1537 (1067–2871) | 0.003 |
| Tumour volume (mL) | 59 (0–2002) | 67 (0–2002) | 30 (0–290) | 0.159 |
| Non-tumour TLV (mL) | 1571 (869–2852) | 1721 (1052–2708) | 1477 (869–2852) | 0.017 |
| Liver function | ||||
| LiMAx value (µg/kg/h) | 326 (95–684) | 337 (188–594) | 301 (95–684) | 0.086 |
| LiMAx/ntTLV (µg/kg/h/mL) | 0.20 (0.06–0.47) | 0.19 (0.10–0.47) | 0.20 (0.06–0.44) | 0.908 |
| Laboratory testing (normal) | ||||
| Bilirubin (mg/dL) (1.2) | 0.7 (0.2–14.3) | 0.7 (0.2–5.6) | 0.7 (0.3–14.3) | 0.540 |
| ALT (U/L) (50) | 32 (15–358) | 34 (15–164) | 32 (16–358) | 0.829 |
| AST (U/L) (38) | 46 (14–224) | 43 (16–211) | 49 (14–224) | 0.423 |
| INR (ratio) | 1.04 (0.82–1.45) | 1.05 (0.82–1.45) | 1.04 (0.90–1.24) | 0.338 |
| C-reactive protein (mg/L) (<5) | 10 (1–187) | 9 (1–187) | 11 (1–172) | 0.208 |
| Creatinin (mg/dL) (0.6–1.1) | 0.9 (0.5–3.8) | 0.9 (0.5–3.8) | 0.7 (0.5–1.5) | <0.001 |
| Albumin (g/L) (35–52) | 36.0 (19.5–45.8) | 36.5 (19.5–45.8) | 35.8 (22.6–42.7) | 0.379 |
| Background liver | ||||
| Metavir | 1 (0–6) | 1 (0–6) | 1 (0–4) | 0.242 |
| Percentage cirrhosis (fibrosis score = 4) | 8.3 | 13.2 | 0.0 | — |
| NAS | 1 (0–4) | 1 (0–4) | 1 (0–4) | 0.435 |
| Percentage severe steatosis (NAS ≥ 5) | 0.0 | 0.0 | 0.0 | — |
| Sinusoidal dilatation score | 0 (0–3) | 0 (0–3) | 0 (0–3) | — |
| Percentage severe dilatation (Grade 3) | 5.3 | 5.7 | 4.5 | 0.663 |
| Percentage with severe background liver disease (Cirrhosis or NAS ≥ 5 or dilatation Grade 3) | 10.5 | 14.3 | 4.5 | 0.243 |
L3 MI, L3 skeletal muscle index; AST, aspartate transaminase; ALT, alanine transaminase; ntTLV, non-tumour total liver volume; NAS, non-alcoholic fatty liver disease (NAFLD) activity score.